Table 4.

Characteristics of non‐selected inpatients and outpatients who maintained sacubitril/valsartan at 7 month follow‐up

	Inpatients n = 83	Outpatients n = 378	P
LVEF, %	31 (25–40)	30.0 (25.0–37.0)	0.40
Variation in LVEF, %	2.0 (0.0–13.0)	1.0 (0.0–5.8)	0.04
Systolic blood pressure, mmHg	120 (104–135)	110 (100–121)	0.002
Variation in systolic blood pressure, mmHg	−5 (−19 to 12)	7 (−2 to 19)	0.02
Heart rate, b.p.m.	65 (58–75)	65 (60–72)	0.83
NYHA functional class			<0.001
I	27 (32.9%)	279 (74.6)
II	49 (59.8%)	74 (19.8)
III	6 (7.3%)	17 (4.5)
IV	0 (0.0%)	4 (1.1)
Improvement of NYHA functional class	52 (64.2%)	306 (72.8%)	0.001
Serum creatinine, mg/dL	1.2 (0.9–1.4)	1.1 (0.9–1.4)	0.51
Variation in serum creatinine, mg/dL	0.0 (−0.2 to 0.2)	0.0 (−0.1 to 0.1)	0.91
Estimated GFR, mL/min	60.0 (49.0–67.0)	60.0 (45.0–73.7)	0.97
Variation in estimated GFR, mL/min	2.0 (−5 to 18)	0.0 (−5 to 6.5)	0.07
Serum potassium, meq/L	4.5 (4.2–4.7)	4.5 (4.2–4.8)	0.55
Variation in serum potassium, meq/L	−0.3 (−0.6 to 0.1)	0.1 (−0.1 to 0.3)	0.55
NT‐proBNP, ng/mL	1809 (767–4117)	1326.0 (618–2673)	0.05
SV dose			<0.001
<50 mg b.i.d.	4 (4.8)	0 (0.0)
50 mg b.i.d.	32 (38.6)	93 (24.6)
100 mg b.i.d.	20 (24.1)	141 (37.3)
200 mg b.i.d.	27 (32.5)	138 (36.5)
Other treatments
Beta‐blockers	76 (91.6)	Not available
MRAs	59 (71.1)	Not available
Loop diuretics	64 (77.1)	Not available
ICD	51 (61.4)	Not available
CRT	14 (16.9)	Not available
Mortality and admissions
All‐cause death	2 (2.4)	6 (1.6)	0.63
Cardiovascular death	0	3 (0.8)	0.41
Hospital admissions	24 (28.9)	43 (11.4)	<0.001

n (%) for categorical variables and median (inter‐quartile range) for continuous variables.

CRT, cardiac resynchronization therapy; GFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B type natriuretic peptide; NYHA, New York Heart Association; SV, sacubitril/valsartan.